Rivus Pharmaceuticals, Inc.

ACTIVE

弗吉尼亚州夏洛茨维尔, 弗吉尼亚州, United Stateswww.rivuspharma.comHolding11–50 employeesEstablished: 2019-01-01

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2019

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

54.5%

Phase 2

45.5%

Trial Status Distribution

Active, not recruiting

9.1%

Completed

72.7%

Recruiting

9.1%

Withdrawn

9.1%

Clinical Trials

Trials sponsored by this organization (11)

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Phase 2

Recruiting

interventional

Feb 2026180 participants

Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6

Phase 1

Completed

interventional

Oct 202559 participants

Relative Bioavailability Study of HU6

Phase 1

Completed

interventional

Jul 202443 participants

A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6

Phase 1

Completed

interventional

Mar 20248 participants

Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Phase 2

Active, not recruiting

interventional

Sep 2023219 participants

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

Phase 2

Completed

interventional

Oct 202267 participants

Safety and Pharmacokinetics of HU6

Phase 1

Completed

interventional

Sep 202230 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations